FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Ferraresso Michael 2. Date of Event Requiring Statement (MM/DD/YYYY)
3/10/2021 

3. Issuer Name and Ticker or Trading Symbol AVEO PHARMACEUTICALS, INC. [AVEO]
(Last)        (First)        (Middle)
C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Commercial Officer /
(Street)
BOSTON, MA 02108      
(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
3/24/2021 

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  917 (1) I  By Spouse 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The shares were inadvertently omitted from the original Form 3 filed by the reporting person and also were omitted from one Form 4 filed by the reporting person after his original Form 3 was filed.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ferraresso Michael
C/O AVEO PHARMACEUTICALS, INC.
30 WINTER STREET
BOSTON, MA 02108


Chief Commercial Officer

Signatures
/s/ Danielle V. Holland, attorney-in-fact 5/13/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more AVEO Pharmaceuticals Charts.
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more AVEO Pharmaceuticals Charts.